# Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

> **NCT00375830** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 114 (actual)

## Conditions studied

- Cancer

## Interventions

- **PROCEDURE:** Bone scan
- **DRUG:** 99mTc-methyl diphosphonate
- **PROCEDURE:** Positron Emission Tomography (PET) scan
- **DRUG:** 18F-Fludeoxyglucose (18F-FDG)
- **PROCEDURE:** Computed Tomography (CT) scan
- **DRUG:** 18F-Sodium Fluoride (18F-NaF)
- **PROCEDURE:** Whole Body Magnetic Resonance Imaging (WB-MRI) scan
- **DRUG:** Gadopentetate dimeglumine
- **DRUG:** Gadofosveset
- **DRUG:** Gadobutrol

## Key facts

- **NCT ID:** NCT00375830
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2017-04-17
- **Final completion:** 2019-03-14
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375830, "Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00375830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*